News & Press Releases

Member Marguerite McConihe was quoted by 9fin in an article about the opportunities and risks associated with the use of AI technologies in leveraged finance. The article notes that while LevFin bankers have largely benefitted from AI, questions are emerging around credit risk, cyber security vulnerabilities, and treating AI-generated assets or IP as debt collateral.

Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599. 

Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.

At Bisnow’s DICE: South event in Dallas this month, Member Jeffrey Moerdler participated in a discussion with other industry leaders about how investors may be overlooking data center acquisitions. Bisnow quoted Jeffrey in a recent article about the takeaways from the event.

In a recent Agenda article, Member Jennifer Rubin shared insights about security and emergency planning for companies facing high-risk incidents. Following the tragic shooting at a Manhattan office building in late July, the piece explores how companies can communicate effectively with investors, maintain strong oversight, and protect employees amid growing concerns about workplace safety.

Mintz advised the lead placement agent in connection with an up to $50 million private placement by Equillium, Inc. The PIPE was comprised of (i) an initial upfront closing of approximately $30 million in gross proceeds in exchange for approximately 52.6 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), and (ii) the potential for up to an additional $20 million in gross proceeds in exchange for up to approximately 35.1 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to achieving specified milestones related to clinical study initiation and share price.